Literature DB >> 16832082

Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy.

Y W Chen1, M E Gurol, J Rosand, A Viswanathan, S M Rakich, T R Groover, S M Greenberg, E E Smith.   

Abstract

OBJECTIVE: To determine the rate of progression of white matter lesions and hemorrhages in a cohort with cerebral amyloid angiopathy (CAA).
METHODS: The authors analyzed data from 26 patients with possible (3) or probable (23) CAA, diagnosed by the Boston Criteria. Brain maps of white matter hyperintensities, normalized to head size (nWMH), were created by blinded computer-assisted segmentation of MRI images obtained at baseline and after a median follow-up interval of 1.1 year.
RESULTS: There was a substantial nWMH volume increase over the interscan interval (median 0.5 mL/year, interquartile range 0.1 to 2.8, p < 0.001). The median yearly increase, expressed as a percentage of the baseline WMH volume, was 18%. The characteristic most strongly associated with nWMH volume increase was the baseline nWMH volume (r = 0.57, p = 0.002). The volume of nWMH progression was also associated with history of cognitive impairment (median 5.0 mL/year in cognitively impaired subjects vs 0.3 mL/year in cognitively unimpaired, p = 0.02) but not age or hypertension. This association remained present in an analysis stratified by baseline WMH volume. New hemorrhages, including asymptomatic microbleeds, were seen in 46% of subjects. The number of new MRI hemorrhages correlated strongly with baseline nWMH (r = 0.53, p = 0.005) but not with nWMH progression (r = 0.22, p = 0.28).
CONCLUSIONS: There is a progressive increase in white matter lesions in subjects with cerebral amyloid angiopathy. The association of white matter lesions with incident lobar hemorrhages suggests that white matter damage may reflect a progressive microangiopathy due to cerebral amyloid angiopathy.

Entities:  

Mesh:

Year:  2006        PMID: 16832082      PMCID: PMC1502246          DOI: 10.1212/01.wnl.0000223613.57229.24

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria.

Authors:  K A Knudsen; J Rosand; D Karluk; S M Greenberg
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

2.  Carotid atherosclerosis and cerebral white matter lesions in a population based magnetic resonance imaging study.

Authors:  F E de Leeuw; J C de Groot; M L Bots; J C Witteman; M Oudkerk; A Hofman; J van Gijn; M M Breteler
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

3.  Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study.

Authors:  Hugh S Markus; Beverley Hunt; Kiran Palmer; Christian Enzinger; Helena Schmidt; Reinhold Schmidt
Journal:  Stroke       Date:  2005-05-19       Impact factor: 7.914

Review 4.  Cerebral amyloid angiopathy and vessel dysfunction.

Authors:  Steven M Greenberg
Journal:  Cerebrovasc Dis       Date:  2002       Impact factor: 2.762

5.  Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage.

Authors:  H C O'Donnell; J Rosand; K A Knudsen; K L Furie; A Z Segal; R I Chiu; D Ikeda; S M Greenberg
Journal:  N Engl J Med       Date:  2000-01-27       Impact factor: 91.245

6.  Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy.

Authors:  T J Grabowski; H S Cho; J P Vonsattel; G W Rebeck; S M Greenberg
Journal:  Ann Neurol       Date:  2001-06       Impact factor: 10.422

7.  Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.

Authors:  M E Gurol; M C Irizarry; E E Smith; S Raju; R Diaz-Arrastia; T Bottiglieri; J Rosand; J H Growdon; S M Greenberg
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

8.  Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice.

Authors:  K Niwa; G A Carlson; C Iadecola
Journal:  J Cereb Blood Flow Metab       Date:  2000-12       Impact factor: 6.200

9.  C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study.

Authors:  E J van Dijk; N D Prins; S E Vermeer; H A Vrooman; A Hofman; P J Koudstaal; M M B Breteler
Journal:  Circulation       Date:  2005-08-01       Impact factor: 29.690

10.  White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study.

Authors:  Reinhold Schmidt; Stefan Ropele; Christian Enzinger; Katja Petrovic; Stephen Smith; Helena Schmidt; Paul M Matthews; Franz Fazekas
Journal:  Ann Neurol       Date:  2005-10       Impact factor: 10.422

View more
  74 in total

Review 1.  The challenge of mixed cerebrovascular disease.

Authors:  Mark Fisher
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

Review 2.  Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates.

Authors:  Jeremy D Schmahmann; Eric E Smith; Florian S Eichler; Christopher M Filley
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 3.  Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?

Authors:  Kellen E Haley; Steven M Greenberg; M Edip Gurol
Journal:  Curr Cardiol Rep       Date:  2013-12       Impact factor: 2.931

Review 4.  Contemplating Alzheimer's disease and the contribution of white matter hyperintensities.

Authors:  Adam M Brickman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

5.  Determinants of white matter hyperintensity burden in patients with Fabry disease.

Authors:  Natalia S Rost; Lisa Cloonan; Allison S Kanakis; Kaitlin M Fitzpatrick; Danielle R Azzariti; Virginia Clarke; Charles M Lourenco; Dominique P Germain; Juan M Politei; György A Homola; Claudia Sommer; Nurcan Üçeyler; Katherine B Sims
Journal:  Neurology       Date:  2016-04-20       Impact factor: 9.910

6.  Setting a gold standard for quantification of leukoaraiosis burden in patients with ischemic stroke: the Atherosclerosis Risk in Communities Study.

Authors:  Natalia S Rost; Saloomeh Sadaghiani; Alessandro Biffi; Kaitlin M Fitzpatrick; Lisa Cloonan; Jonathan Rosand; Dean K Shibata; Thomas H Mosley
Journal:  J Neurosci Methods       Date:  2014-01-15       Impact factor: 2.390

Review 7.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.

Authors:  Reisa A Sperling; Clifford R Jack; Sandra E Black; Matthew P Frosch; Steven M Greenberg; Bradley T Hyman; Philip Scheltens; Maria C Carrillo; William Thies; Martin M Bednar; Ronald S Black; H Robert Brashear; Michael Grundman; Eric R Siemers; Howard H Feldman; Rachel J Schindler
Journal:  Alzheimers Dement       Date:  2011-07       Impact factor: 21.566

8.  Critical care management of acute intracerebral hemorrhage.

Authors:  Joshua N Goldstein; Aaron J Gilson
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

9.  Impaired visual evoked flow velocity response in cerebral amyloid angiopathy.

Authors:  E E Smith; M Vijayappa; F Lima; P Delgado; L Wendell; J Rosand; S M Greenberg
Journal:  Neurology       Date:  2008-10-28       Impact factor: 9.910

10.  Cerebral microbleeds in a multiethnic elderly community: demographic and clinical correlates.

Authors:  Anne F Wiegman; Irene B Meier; Nicole Schupf; Jennifer J Manly; Vanessa A Guzman; Atul Narkhede; Yaakov Stern; Sergi Martinez-Ramirez; Anand Viswanathan; José A Luchsinger; Steven M Greenberg; Richard Mayeux; Adam M Brickman
Journal:  J Neurol Sci       Date:  2014-07-18       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.